Purchase Order VA580N19445
- Not listed
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 firm fixed-price purchase order is for the Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of January 20, 2011. Regenesis Biomedical has provided the Provant Therapy System and related rental...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 firm-fixed-price purchase order is for the company's Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of May 8, 2011 and was awarded through Regenesis Biomedical's existing GSA Schedule...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $7,142.85 firm fixed-price purchase order contract is for the provision of Regenesis Biomedical's Provant Therapy System, a patented noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract is not associated with any set-aside designations. Regenesis Biomedical,...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company, for the provision of the Provant Therapy System, a noninvasive regenerative medicine product. The $4,820.98 firm-fixed-price purchase order contract was awarded on January 10, 2011, with a completion date of February 10, 2011. The contract was awarded under Regenesis Biomedical's General Services Administration (GSA) Schedule 65-II-A for...
- This federal contract award to Regenesis Biomedical Inc. was made by the Department of Veterans Affairs (VA) for the provision of the Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The $3,645.14 firm fixed-price purchase order contract has a completion date of June 16, 2011. Regenesis Biomedical is the prime contractor providing its proprietary medical device directly to the VA, with no subcontractors...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 firm-fixed-price purchase order is for the Provant Therapy System, a noninvasive regenerative medicine product developed and patented by Regenesis Biomedical. The contract does not utilize any set-aside designations. Based on the information provided, Regenesis Biomedical acts as the prime contractor and does not subcontract...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company. The $4,820.98 firm-fixed-price purchase order is for the company's proprietary Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract was issued under Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies,...
- This federal contract award is for the procurement of the Provant Therapy System, a noninvasive regenerative medicine product developed by Regenesis Biomedical Inc. The contract, valued at $4,820.98, was awarded to Regenesis Biomedical Inc. by the Department of Veterans Affairs (VA) on June 21, 2011, with an ultimate completion date of July 21, 2011. The contract is a firm fixed-price purchase order, and it does not utilize any set-aside designations. Regenesis Biomedical Inc. is the prime...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company that develops and markets noninvasive regenerative medicine products. The $4,820.98 firm-fixed-price purchase order is for Regenesis Biomedical's Provant Therapy System, a patented medical device indicated for palliative treatment of post-operative pain and edema. The contract has a performance period through March 16, 2011 and was not set aside for...
- This federal contract award, valued at $7,055.10, was issued by the U.S. Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company. The contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract does not have a set-aside designation and is structured as a firm-fixed-price purchase order. Regenesis Biomedical...
This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 firm-fixed-price purchase order is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of January 27, 2011. Regenesis Biomedical is the prime contractor and does not utilize any subcontractors for this award. The contract was not set aside for any preferential procurement program. Regenesis Biomedical has been registered in the System for Award Management (SAM.gov) database since 2004 to pursue federal contracting opportunities, primarily with the VA, for the Provant Therapy System and related rental services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 12/20/10 |